FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667051> ?p ?o ?g. }

• W4385667051 endingPage "e6102468" @default.
• W4385667051 startingPage "e6102468" @default.
• W4385667051 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM) treated with standard of care therapy have median overall survival (OS) of ~12 months. In the single-arm, phase 1b/2 CARTITUDE-1 study (NCT03548207), patients received a single infusion of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor-T cell therapy targeting B-cell maturation antigen. At the final protocol-specified analysis (27.7-month median follow-up), overall response rate (ORR) was 98%, with 83% stringent complete response; 27-month rates of progression-free survival (PFS) and OS were 55% and 70%, respectively. Aims: To report CARTITUDE-1 study close out efficacy and safety results. Methods: Informed consent was obtained prior to study entry. Enrolled patients had received ≥3 prior lines of therapy (LOT) or were double refractory to a proteasome inhibitor (PI) and immunomodulatory drug (IMiD); and had received prior PI, IMiD, and anti-CD38 antibody therapy. Primary endpoint was ORR and safety; secondary endpoints included PFS, OS, and minimal residual disease (MRD)-negativity at 10-5. Results: 97 patients received cilta-cel (59% male; median age 61 years; median of 6 prior LOT; 42% penta-drug refractory; 88% triple-class refractory; 99% refractory to last LOT). As of October 14, 2022, median follow-up was 33.4 months (range, 1.5−45.2). Median duration of response was 33.9 month (95% CI, 25.5–not estimable [NE]). Median PFS was 34.9 months (95% CI, 25.2–NE), with an estimated 47.5% of patients progression free and alive at 36 months. Median OS was not reached, with an estimated 62.9% survival at 36 months. Of 49 MRD-evaluable patients, 26 had MRD-negativity sustained for ≥12 months, of which 20 had sustained MRD-negative complete response (CR) or better. Median PFS was not reached in these subgroups (Table). Eighteen patients were MRD-negative with ≥CR at 24-months post infusion. No new safety signals and no new neurotoxicity events were reported since the 27.7-month median follow-up. Six new cases of second primary malignancy were reported, including 2 cases of basal cell carcinoma and 1 case each of myelodysplastic syndrome, B-cell lymphoma, melanoma, and prostate cancer. Five additional deaths occurred (progressive disease [PD], n=3; pneumonia and sepsis, n=1 each [both unrelated to cilta-cel]), for a total of 35 deaths (PD, n=17; unrelated to cilta-cel, n=12; related, n=6). Summary/Conclusion: Longer median PFS was observed after a single infusion of cilta-cel than any previously reported therapy in heavily pretreated patients with RRMM. Achieving CR and/or sustained MRD-negativity was associated with prolonged PFS. Patients continue to be followed for safety and survival in the 15-year CARTINUE long-term study (NCT05201781; MMY4002). © 2023 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2023 ASCO Annual Meeting. All rights reserved.Keywords: Phase I/II, Clinical trial, CAR-T, Multiple myeloma" @default.
• W4385667051 created "2023-08-09" @default.
• W4385667051 creator A5008309494 @default.
• W4385667051 creator A5009026971 @default.
• W4385667051 creator A5009378735 @default.
• W4385667051 creator A5010627919 @default.
• W4385667051 creator A5014158343 @default.
• W4385667051 creator A5016118775 @default.
• W4385667051 creator A5022228597 @default.
• W4385667051 creator A5022766377 @default.
• W4385667051 creator A5025168585 @default.
• W4385667051 creator A5028046297 @default.
• W4385667051 creator A5032617342 @default.
• W4385667051 creator A5045740077 @default.
• W4385667051 creator A5048369262 @default.
• W4385667051 creator A5050961257 @default.
• W4385667051 creator A5051092535 @default.
• W4385667051 creator A5055832458 @default.
• W4385667051 creator A5057090502 @default.
• W4385667051 creator A5057911528 @default.
• W4385667051 creator A5090694142 @default.
• W4385667051 creator A5092083444 @default.
• W4385667051 date "2023-08-01" @default.
• W4385667051 modified "2023-10-16" @default.
• W4385667051 title "S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA" @default.
• W4385667051 doi "https://doi.org/10.1097/01.hs9.0000967720.61024.68" @default.
• W4385667051 hasPublicationYear "2023" @default.
• W4385667051 type Work @default.
• W4385667051 citedByCount "0" @default.
• W4385667051 crossrefType "journal-article" @default.
• W4385667051 hasAuthorship W4385667051A5008309494 @default.
• W4385667051 hasAuthorship W4385667051A5009026971 @default.
• W4385667051 hasAuthorship W4385667051A5009378735 @default.
• W4385667051 hasAuthorship W4385667051A5010627919 @default.
• W4385667051 hasAuthorship W4385667051A5014158343 @default.
• W4385667051 hasAuthorship W4385667051A5016118775 @default.
• W4385667051 hasAuthorship W4385667051A5022228597 @default.
• W4385667051 hasAuthorship W4385667051A5022766377 @default.
• W4385667051 hasAuthorship W4385667051A5025168585 @default.
• W4385667051 hasAuthorship W4385667051A5028046297 @default.
• W4385667051 hasAuthorship W4385667051A5032617342 @default.
• W4385667051 hasAuthorship W4385667051A5045740077 @default.
• W4385667051 hasAuthorship W4385667051A5048369262 @default.
• W4385667051 hasAuthorship W4385667051A5050961257 @default.
• W4385667051 hasAuthorship W4385667051A5051092535 @default.
• W4385667051 hasAuthorship W4385667051A5055832458 @default.
• W4385667051 hasAuthorship W4385667051A5057090502 @default.
• W4385667051 hasAuthorship W4385667051A5057911528 @default.
• W4385667051 hasAuthorship W4385667051A5090694142 @default.
• W4385667051 hasAuthorship W4385667051A5092083444 @default.
• W4385667051 hasBestOaLocation W43856670511 @default.
• W4385667051 hasConcept C121332964 @default.
• W4385667051 hasConcept C126322002 @default.
• W4385667051 hasConcept C141071460 @default.
• W4385667051 hasConcept C142424586 @default.
• W4385667051 hasConcept C143998085 @default.
• W4385667051 hasConcept C203092338 @default.
• W4385667051 hasConcept C2776364478 @default.
• W4385667051 hasConcept C2776694085 @default.
• W4385667051 hasConcept C2780739268 @default.
• W4385667051 hasConcept C535046627 @default.
• W4385667051 hasConcept C71924100 @default.
• W4385667051 hasConcept C87355193 @default.
• W4385667051 hasConcept C90924648 @default.
• W4385667051 hasConceptScore W4385667051C121332964 @default.
• W4385667051 hasConceptScore W4385667051C126322002 @default.
• W4385667051 hasConceptScore W4385667051C141071460 @default.
• W4385667051 hasConceptScore W4385667051C142424586 @default.
• W4385667051 hasConceptScore W4385667051C143998085 @default.
• W4385667051 hasConceptScore W4385667051C203092338 @default.
• W4385667051 hasConceptScore W4385667051C2776364478 @default.
• W4385667051 hasConceptScore W4385667051C2776694085 @default.
• W4385667051 hasConceptScore W4385667051C2780739268 @default.
• W4385667051 hasConceptScore W4385667051C535046627 @default.
• W4385667051 hasConceptScore W4385667051C71924100 @default.
• W4385667051 hasConceptScore W4385667051C87355193 @default.
• W4385667051 hasConceptScore W4385667051C90924648 @default.
• W4385667051 hasIssue "S3" @default.
• W4385667051 hasLocation W43856670511 @default.
• W4385667051 hasLocation W43856670512 @default.
• W4385667051 hasOpenAccess W4385667051 @default.
• W4385667051 hasPrimaryLocation W43856670511 @default.
• W4385667051 hasRelatedWork W2081790265 @default.
• W4385667051 hasRelatedWork W2139647583 @default.
• W4385667051 hasRelatedWork W2183237771 @default.
• W4385667051 hasRelatedWork W2589963932 @default.
• W4385667051 hasRelatedWork W2789668336 @default.
• W4385667051 hasRelatedWork W4231598961 @default.
• W4385667051 hasRelatedWork W4285091731 @default.
• W4385667051 hasRelatedWork W4285492859 @default.
• W4385667051 hasRelatedWork W4308189788 @default.
• W4385667051 hasRelatedWork W4380150309 @default.
• W4385667051 hasVolume "7" @default.
• W4385667051 isParatext "false" @default.
• W4385667051 isRetracted "false" @default.
• W4385667051 workType "article" @default.